Herpes simplex virus 1 (HSV-1) infects several billion people worldwide and can cause life-threatening herpes simplex encephalitis (HSE) in some patients. Monogenic defects in components of the type I interferon system have been identified in patients with HSE, emphasizing the role of inborn errors of immunity underlying HSE pathogenesis. Here, we identify compound heterozygous loss-of-function mutations in the gene GTF3A encoding for transcription factor IIIA (TFIIIA), a component of the RNA polymerase III complex, in a patient with common variable immunodeficiency and HSE. Patient fibroblasts and GTF3A gene–edited cells displayed impaired HSV-1–induced innate immune responses and enhanced HSV-1 replication. Chromatin immunoprecipitation sequencing analysis identified the 5 S ribosomal RNA pseudogene 141 ( RNA5SP141 ), an endogenous ligand of the RNA sensor RIG-I, as a transcriptional target of TFIIIA. GTF3A mutant cells exhibited diminished RNA5SP141 expression and abrogated RIG-I activation upon HSV-1 infection. Our work unveils a crucial role for TFIIIA in transcriptional regulation of a cellular RIG-I agonist and shows that GTF3A genetic defects lead to impaired cell-intrinsic anti–HSV-1 responses and can predispose to HSE.
Self-amplifying RNA (sa-RNA) technology is a promising strategy for vaccine design, as its intracellular replication boosts transgene expression and provides self-adjuvanticity. However, sa-RNA efficiency is limited by innate immune responses triggered by the presence of intracellular double-stranded RNA (dsRNA). In vertebrates, differentiated cells mainly use type I interferon (IFN) system for protection against viruses, while stem cells rely on IFN-independent mechanisms such as antiviral RNA interference (RNAi). Here, we found that the efficiency of sa-RNAs based on chikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) genomes is enhanced when co-expressed in cis with the Nodamura virus (NoV) B2 protein, a viral suppressor of RNAi. In stem cells, NoV B2 prevents Dicer-mediated processing of dsRNA, while in somatic cells, it blocks the translation shutdown caused by protein kinase R (PKR), a key effector of the IFN system. Notably, NoV B2 does not interfere with IFN induction and signalling, preserving sa-RNA’s self-adjuvant properties. Mechanistically, NoV B2 sequesters replication-derived dsRNA at the cell periphery, offering a novel strategy to boost sa-RNA efficiency without compromising its immune stimulatory properties. Graphical
Self-amplifying RNA (saRNA) offers a powerful approach for vaccine development, as its replicative nature within cells provides prolonged antigen expression together with self-adjuvanticity. However, its potency is often limited by innate immune responses, particularly those triggered by intracellular double-stranded RNA (dsRNA), highlighting the need for strategies that can boost saRNA efficacy without compromising its immunostimulatory properties. Here we show that the cis -expression of the Nodamura virus (NoV) B2 protein markedly enhances saRNA-driven transgene expression by alleviating key cell-intrinsic antiviral effectors. In stem cells, NoV B2 limits the accumulation of Dicer-generated viral small RNAs, consistent with suppression of antiviral RNA interference, while in somatic cells, it prevents protein kinase R (PKR)-driven translational shutdown. NoV B2 sequesters dsRNA at the cell periphery, shielding it from antiviral effectors without suppressing type I interferon induction or signalling, thereby preserving saRNA’s immunostimulatory properties, while enhancing its transgene expression potential. These findings reveal a strategy to overcome intracellular antiviral restriction of saRNA while preserving adjuvanticity, with implications for the design of more effective saRNA-based vaccines and therapeutics.